Skip to main content

Table 3 Association of age group with site of metastasis and 1st LoT treatment modality for patients treated with 1st LoT SACT

From: Systemic treatment of hormone receptor positive, human epidermal growth factor 2 negative metastatic breast cancer: retrospective analysis from Leeds Cancer Centre

 

Age group (years)

χ2

< 55 (n = 33)

55–74 (n = 95)

75+ (n = 53)

total

All (n = 181)

Non-visceral only

8 (24.2%)

39 (41.1%)

19 (35.8%)

66 (36.5%)

p = 0.223

Visceral

25 (75.8%)

56 (58.9%)

34 (64.2%)

115 (63.5%)

Non-visceral mets only (n = 66)

Chemo

< 6

< 6

< 6

< 6

p = 0.495a

Endo +/−targ

7 (87.5%)

37 (94.9%)

17 (89.5%)

61 (92.4%)

Visceral mets (incl. brain) (n = 115)

Chemo

17 (68.0%)

22 (39.3%)

< 6

41 (35.7%)

p < 0.001

Endo +/−targ

8 (32.0%)

34 (60.7%)

32 (94.1%)

74 (64.3%)

All (n = 181)

Chemo

18 (54.5%)

24 (25.3%)

< 6

46 (25.4%)

p < 0.001

Endo +/−targ

15 (45.5%)

71 (74.7%)

49 (92.5%)

135 (74.6%)

  1. aFreeman-Halton Fisher exact test statistic
  2. Chemo Chemotherapy, Endo +/−targ Endocrine (with or without targeted) therapy
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us